Mifepristone Policy Review by FDA Director

In a recent conversation, Food and Drug Administration Director Marty McCurry expressed that he approached the review of mifepristone, a medication used to terminate pregnancies up to ten weeks, without any preconceptions. He emphasized the importance of staying open-minded and listening to various perspectives when making decisions.

“Right now, we’re reviewing safety data on mifepristone. This is something that has been required by previous administrations,” McCurry mentioned in his interview. He underscored the necessity of being receptive to different opinions and making informed choices.

During a World Economy Summit in April, he reassured attendees that there were no immediate plans to restrict access to abortion medications. However, he did note that the FDA would act if any safety concerns were substantiated by emerging data.

Concerns Over Mifepristone

McCurry further pointed out that an ongoing assessment of mifepristone’s safety might prompt action if indicators suggested a potential risk. This comes against the backdrop of growing scrutiny surrounding the drug and abortion medications in general, particularly from some healthcare professionals who have raised alarms about their safety.

Moreover, Senator Josh Hawley from Missouri wrote to McCurry, voicing his unease about mifepristone’s safety. He indicated that it is essential to realign necessary safeguards for its use as women’s health hinges on these concerns.

In light of these discussions, McCurry intends to keep tabs on the evolving data but reiterated that, as of now, the intention is not to alter existing policies on mifepristone. He acknowledged the ongoing dialogue with those expressing apprehensions about the drug’s safety.

Fox News Digital has reached out to both the FDA and Senator Hawley for additional comments, but it seems the debate over mifepristone is poised to continue, reflecting broader conversations surrounding abortion and women’s health.